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Background: Cetuximab, an anti-EGFR monoclonal antibody, is used to treat several cancers. However, many
patients who initially respond to cetuximab acquire resistance. To examine mechanisms of acquired resistance, we
developed a series of cetuximab-resistant (CtxR) clones derived from the cetuximab sensitive (CtxS) non-small cell
lung cancer (NSCLC) cell line H226. Previous studies characterizing this model revealed that: 1) EGFR was robustly
overexpressed in CtxR clones due to decreased EGFR ubiquitination and degradation and 2) CtxR clones expressed
increased HER2 and HER3 activation resulting in constitutive activation of the PI3K/AKT signaling axis. These findings
suggest that dual targeting HER family receptors would be highly beneficial in the CtxR setting.
Results: Since HER3 has been implicated in resistance to EGFR inhibitors, the efficacy of dually targeting both EGFR
and HER3 in CtxR models was evaluated. First, EGFR and HER3 expression were knocked down with siRNAs. Compared
to the CtxS parental cell line (HP), all CtxR clones exhibited robust decreases in cell proliferation upon dual knockdown.
Analysis of CtxR clones indicated that neuregulin-1 was highly overexpressed compared to HP cells. Incubation of HP
cells with neuregulin-1 rendered them resistant to cetuximab. Next, dual treatment of CtxR clones with cetuximab and
the HER3 neutralizing monoclonal antibody (mAb) U3-1287 led to potent anti-proliferative effects. Blockade of EGFR
with cetuximab resulted in inactivation of MAPK, while blockade of HER3 with U3-1287 resulted in the inactivation of
AKT. Treatment with both mAbs resulted in knockdown of both signaling pathways simultaneously. HER2 was also
strongly inactivated upon dual mAb therapy, suggesting that this treatment regimen can diminish signaling from three
HER family receptors. De novo CtxR H226 mouse xenografts were established to determine if dual therapy could overcome
acquired resistance to cetuximab in vivo. Tumors that had acquired resistance to cetuximab were significantly growth
delayed upon dual treatment of U3-1287 and cetuximab compared to those continued on cetuximab only.
Combinatorial-treated xenograft tumors expressed decreased Ki67 and increased cleaved caspase-3 levels compared to
tumors treated with either monotherapy.
Conclusions: These studies demonstrate that dually targeting HER family receptors with antibody-based therapies can
overcome acquired resistance to cetuximab.
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The HER family receptor tyrosine kinases (RTK) play crit-
ical roles in cell physiology, development, and cancer
pathophysiology. This family consists of four members:
EGFR, HER2, HER3 and HER4. These receptors are acti-
vated on the cell surface through binding to cognate li-
gands, leading to receptor homo- and hetero-dimerization
with other HER family members. Dimerization of HER
family receptors leads to the activation of each receptor’s
tyrosine kinase, and subsequent activation of multiple
downstream effector molecules [1,2]. Specifically, EGFR
regulates the RAS/RAF/MEK/ERK (also known as the
MAPK) and PI3K/AKT signaling pathways, both of which
have been attributed to increased cellular proliferation,
survival, angiogenesis, and invasion.
Overexpression or hyperactivation of the EGFR is asso-
ciated with poor prognosis in many human cancers, in-
cluding metastatic colorectal cancer (mCRC), head and
neck squamous cell carcinoma (HNSCC), non-small cell
lung cancer (NSCLC) and brain cancer [3-6]. Therefore,
targeting EGFR has been intensely pursued over the last
three decades as a cancer treatment strategy. One ap-
proach uses monoclonal antibodies (mAbs) to target the
extracellular domain of the EGFR to block natural ligand
binding. Cetuximab (ICM-225, Erbitux) is a human: mur-
ine chimeric mAb that binds to extracellular domain III of
the EGFR. This interaction partially blocks the ligand-
binding domain and sterically hinders the correct ex-
tended conformation of the dimerization arm located on
domain II [7]. The Food and Drug Administration (FDA)
has approved cetuximab for treatment of patients with
mCRC and HNSCC [8,9], with more recent reports indi-
cating clinical benefit for the treatment of NSCLC [10,11].
Unfortunately, clinical data suggests that the majority of
patients whom initially respond to cetuximab eventually
acquire resistance [12-14].
Based on these clinical reports, a large effort has been
undertaken to define the molecular mechanisms that under-
lie acquired resistance to cetuximab [15-22]. To do this, our
laboratory has previously established a model of acquired re-
sistance to cetuximab by exposing the cetuximab-sensitive
(CtxS) NSCLC cell line H226 to increasing concentrations
of cetuximab until single cell resistant clones emerged [18].
Studies of this model cell system indicated that CtxR cells
contained increased steady state expression and hyperactiva-
tion of the EGFR due to impaired internalization and deg-
radation [18]. It was also shown that CtxR clones had
increased EGFR-dependent activation of HER3 [18]. Con-
sistent with this finding, several studies have revealed that
resistance to anti-EGFR therapeutics may be due to subse-
quent activation of HER3 signaling pathways [23-26]. The
HER3 receptor has been shown to be an important
dimerization partner with EGFR, HER2 and c-MET which
leads to sustained activity of the AKT signaling pathway[18,23,27-30]. Similar to EGFR, HER3 expression is as-
sociated with poor clinical outcome in lung, breast,
ovarian and colon cancers [31-34]. These findings have
led to the development of anti-HER3 therapeutics, one
of which includes the fully humanized mAb U3-1287.
Preclinical studies have indicated that U3-1287 binding
to the extracellular region of HER3 led to its internaliza-
tion and subsequent degradation in models of breast,
lung, and head and neck cancer [35-37].
In the current study, we hypothesized that CtxR clones
and tumors may benefit by the dual targeting of EGFR
and HER3. We found that cetuximab and U3-1287 dual
therapy led to the inhibition of cellular proliferation and
survival pathways in CtxR clones, while single agent
therapy had minimal effect. Caspase-3/7 and annexin-V
assays indicated a significant increase in apoptosis in
cells treated with dual therapy compared to either agent
alone. Moreover, growth of CtxR tumors treated with
cetuximab and U3-1287 were significantly delayed com-
pared to mice continued on cetuximab monotherapy.
Analysis of combinatorial-treated xenograft tumors dem-
onstrated decreased activation of HER2, HER3 and Ki67
as well as a modest increase in cleaved caspase-3 com-
pared to tumors treated with monotherapy. The results
presented herein suggest that dual targeting HER family
receptors with antibody-based therapies can overcome ac-
quired resistance to cetuximab.
Results
Cetuximab-resistant (CtxR) clones have increased HER
family receptor activity
We previously reported that CtxR clones (HC1, HC4 and
HC8) exhibited increased expression and activity of EGFR
relative to the CtxS parental control cells (HP) [18]. In
addition, HER3 expression and phosphorylation were in-
creased in CtxR clones, as well as the phosphorylation of
HER2 and the downstream effector molecules AKT, MAPK,
p90-RSK and STAT3 (Figure 1A). Quantifying EGFR and
HER3 on the cell surface by flow cytometry indicated
that there was greater plasma membrane expression of
EGFR and HER3 in CtxR clones compared to HP cells
(Figure 1B). Further, immunoprecipitation analysis in-
dicated that EGFR and HER3 were highly associated in
CtxR clones, while this association was absent in CtxS
HP cells (Figure 1C). Taken together these data suggest
that prolonged exposure to cetuximab leads to increased
expression and association of EGFR and HER3, as well as
increased activation of HER2.
CtxR clones depend on EGFR and HER3 for proliferation
and cetuximab resistance
To determine if cells with acquired resistance to cetuximab
depend on EGFR and/or HER3 signaling, proliferation
assays using small interfering RNAs (siRNA) targeting
Figure 1 Cetuximab-resistant (CtxR) clones have increased HER family receptor activity. (A) CtxR cells have increased HER family activity as
well as phosphorylation levels of downstream signaling molecules. Parental (HP) and CtxR clones (HC1, HC4, HC8) were harvested and protein
lysates were fractionated on SDS-PAGE followed by Immunoblotting for the indicated proteins. α-Tubulin was used as a loading control. (B) Expression
of EGFR and HER3 on the plasma membrane is increased in CtxR clones compared to cetuximab-sensitive (CtxS) cells (HP). The levels of EGFR and
HER3 on the cell surface were measured by flow cytometry. (n = 3) (C) EGFR displayed increased association with HER3 in all three CtxR clones
compared to CtxS HP cell line. Cells were harvested and EGFR or HER3 were immunoprecipitated with anti-rabbit EGFR antibody or anti-rabbit HER3
antibody. The immunoprecipitate complexes were fractionated on SDS-PAGE followed by immunoblotting for indicated proteins.
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CtxR clones showed greater inhibition of proliferation
when transfected with both siRNAs compared to either
siRNA alone. Interestingly, siHER3 alone did not augment
proliferation, indicating minimal utility of targeting only
HER3 in CtxR clones. Immunoblot analysis validated
knockdown of each target per treatment group (Figure 2A).
Since siHER3 impaired the proliferation of CtxR clones
only upon knockdown of EGFR expression, we next
sought to identify if ligand induced activation of HER3
may mediate cetuximab resistance. First, quantitative
PCR (qPCR) was used to analyze neuregulin-1 (NRG-1)
expression in CtxR clones compared to HP parental cells
(Figure 2B), where there was a 20–40 fold increase in
NRG-1 expression in all CtxR clones. This large increasein HER3 ligand expression suggested that autocrine
activation of HER3 may mediate cetuximab resist-
ance. To test this hypothesis, we next stimulated the
CtxS parental HP cells with NRG-1 to assess if this
would lead to increased resistance to cetuximab. Addition
of NRG-1 to HP cells resulted in resistance to increasing
doses of cetuximab treatment (Figure 2C). Analysis of
downstream signaling molecules indicated that HP cells
stimulated with NRG-1 had robust activation of all three
HER family receptors, in addition to AKT and MAPK
effector kinases. The activation of these molecules was
not inhibited by cetuximab in the presence of NRG-1.
This result suggests that activation of HER3 can stimu-
late cells to regulate cell proliferation and survival path-
ways, and thus bypass the inhibitory effects of cetuximab.
Figure 2 (See legend on next page.)
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Figure 2 CtxR clones depend on EGFR and HER3 for proliferation and cetuximab response. (A) Effects of EGFR and HER3 knockdown on
proliferation of CtxR cells. Proliferation was measured at 72 h after treatment using the crystal violet assay. Data points are represented as
mean ± s.e.m (n = 3). *p ≤0.05. Whole cell lysates were harvested after 72 h treatment and fractionated on SDS-PAGE followed by immunoblotting
for the indicated proteins. α-Tubulin was used as a loading control. (B) Upregulation of NRG-1 ligand in CtxR clones by real-time qPCR. NRG-1 expression
level in CtxR clones HC1, HC4 and HC8 was measured by real-time qPCR analysis. Data are represented as fold increase relative to the HP parental control.
Data points are represented as mean ± s.e.m. (n = 4). (C) NRG-1 ligands can enhance cetuximab resistance in cetuximab-sensitive cells. Proliferation was
measured at 72 h after treatment using CCK8 assays and plotted as a percentage of proliferation relative to the vehicle cells. Data points are represented
as mean ± s.e.m. (n = 4). (D) NRG-1 increased phosphorylation levels of HER family receptors and their respective kinase targets in HP cells. Whole cell
lysates were harvested and fractionated on SDS-PAGE followed by immunoblotting for the indicated proteins. α-Tubulin was used as a loading control.
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with EGFR to regulate cellular proliferation and cetuxi-
mab response.
Dual blockade of HER3 and EGFR can effectively inhibit
the proliferation of CtxR clones
To further investigate if HER3 plays a role in CtxR cellular
proliferation, CtxR clones were treated with increasing
concentrations of the anti-HER3 monoclonal antibody
U3-1287 for 72 h. Results of this experimentation indi-
cated that U3-1287 monotherapy did not significantly affect
cellular proliferation of CtxR clones (Figure 3A), consistentFigure 3 U3-1287 downregulates total and phosphorylation of
HER3 as well as AKT phosphorylation, but does not inhibit cell
proliferation in CtxR clones. (A) U3-1287 alone did not inhibit cell
proliferation in CtxR clones. The cell proliferation was measured via
crystal violet assay and plotted as a percentage of proliferation relative
to the vehicle control cells. Data points are represented as mean ± s.e.m.
(n = 3). (B) U3-1287 downregulates total HER3 and phosphorylation of
AKT in CtxR clones. Whole cell lysates were fractionated on SDS-PAGE
followed by immunoblotting for the indicated proteins. α-Tubulin was
used as a loading control.with siHER3 data presented in Figure 2A. Examination of
U3-1287 treated cells indicated that HER3 was effectively
degraded upon treatment, even at low doses (1 ug/mL). A
dose dependent decrease in the phosphorylation of AKT on
S473 was also observed. Overall, these findings indicate that
U3-1287 can effectively target HER3 in CtxR clones
however, there was minimal effect on proliferation by
monotherapy.
Since dual knockdown of EGFR and HER3 led to po-
tent anti-proliferative effects in CtxR clones (Figure 2A),
we hypothesized that cetuximab in combination with
U3-1287 may produce a anti-proliferative response. Thus,
cell proliferation analysis was performed after treatment
of CtxR clones with vehicle, cetuximab (20 ug/ml), U3-
1287 (100 ug/mL) or the combination of cetuximab and
U3-1287. The results of these experiments indicated that
while cetuximab or U3-1287 monotherapy did not affect
the proliferation of CtxR clones, the combination of the
two drugs showed significant anti-proliferative effects
(Figure 4A).
We further investigated if EGFR or HER3 activation was
inhibited by combined treatment with U3-1287 and cetux-
imab. CtxR clones were treated with vehicle, 20 ug/mL
cetuximab, 100 ug/mL U3-1287 or combinatorial treat-
ment for 24 h. Analysis of EGFR and HER3 protein levels
post treatment indicated that HER3 was robustly degraded
by U3-1287 or dual treatment in CtxR clones, while total
and activated EGFR (Y1173) was not affected with either
treatment (Figure 4B). Interestingly, treatment with cetux-
imab led to modest increases in expression of total levels
of HER3 in both CtxR clones and HP cells as well as
phopho-HER3 levels in CtxR clones.
Combined treatment with cetuximab and U3-1287 leads
to impaired HER2, AKT and MAPK signaling
Since the combination of U3-1287 and cetuximab resulted
in strong anti-proliferative effects in CtxR clones (Figure 4A),
we investigated which downstream pathways were im-
paired. Human Phospho-Kinase array analysis on CtxR
clone (HC4) treated with vehicle, cetuximab (20 ug/mL),
U3-1287 (100 ug/mL) or the combination of cetuxi-
mab and U3-1287 for 24 hours was performed. This
human Phospho-Kinase array contains antibodies to
Figure 4 Dual blockade of HER3 and EGFR can effectively inhibit the proliferation of CtxR clones. (A) Combinatorial treatment of CtxR
clones with cetuximab and U3-1287 leads to proliferation inhibition. Cell proliferation was measured using crystal violet assay and plotted as a
percentage of proliferation relative to the vehicle control cells. Data points are represented as mean ± s.e.m. (n = 3). (B) Combinatorial treatment
with cetuximab and U3-1287 leads to loss of HER3 expression in CtxR clones. Protein lysates were fractionated on SDS–PAGE followed by immunoblotting
for the indicated proteins. α-Tubulin was used as a loading control.
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proliferation and survival. Quantitation of phosphorylated
proteins was completed using scanned images from ImageJ
software for each treatment and were summarized in Fig-
ure 5A. Combined treatment with U3-1287 and cetuximab
inhibited several downstream EGFR and HER3 pathways in-
cluding pERK1/2 (pMAPK), pAKT, pRSK1/2/3, STAT5β,
and STAT3. The inhibition of these downstream targets was
validated in all three CtxR clones and HP cells by immuno-
blot analysis. Combinatorial treatment of U3-1287 and
cetuximab for 24 hours resulted in decreased levels of phos-
phorylated AKT, MAPK, RSK1 and STAT3 in CtxR clones
(Figure 5B). Phosphorylation of HER2 on tyrosine 1248
(Y1248) in HP cells was inhibited by cetuximab treatment
alone, while HER2 phosphorylation in all three CtxR clones
was strongly inhibited only by the combination treatment.
These results indicate that the dual targeting of EGFR andHER3 lead to a robust inhibition of HER2 as well as AKT
and MAPK signaling pathways.
Combined treatment with cetuximab and U3-1287 promotes
apoptosis in CtxR clones
We demonstrated that combined EGFR and HER3 knock-
down inhibited cell proliferation in CtxR clones more than
knockdown of either gene alone. To see if combinatorial
treatment of CtxR clones led to increased apoptosis,
caspase-3/7 activity and Annexin-V analyses were con-
ducted after 24 h treatment with vehicle, 20 ug/mL
cetuximab, 50 ug/mL U3-1287 or both antibodies. CtxR
clones treated with dual therapy demonstrated robust in-
creases in caspase-3/7 activity (~2-3 fold) indicative of
cells actively undergoing apoptosis, while single therapy
treatment did not increase caspase-3/7 activity over vehicle
treated cells (Figure 6A). Further, Annexin-V analysis by
Figure 5 Combined treatment of CtxR clones with cetuximab and U3-1287 inhibits HER2, AKT and MAPK signalings more effectively
than either drug alone. (A) Human Phospho-Kinase array analysis demonstrated that combined treatment with cetuximab and U3-1287 inhibits
proliferation and survival signaling in CtxR cell clone, HC4. The cell extracts were incubated with membranes containing antibodies to 46 different
kinase phosphorylation sites. Quantitation of phosphorylated proteins was completed using scanned images from ImageJ software. Data points
are represented as the mean of duplicate spots. (B) Effects of combined cetuximab and U3-1287 treatment on their respective kinase targets in
CtxR clones. Protein lysates from Figure 5A (HC4) were fractionated on SDS–PAGE followed by immunoblotting for the indicated proteins. Protein
lysate from other CtxR clones (HC1 and HC8) as well as HP cells were obtained after treatment with vehicle, cetuximab (20 ug/mL), U3-1287 (100
ug/mL) or the combination of cetuximab and U3-1287 for 24 h. α-Tubulin was used as a loading control.
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in apoptosis by combination treatment in all CtxR clones
(16-19%) compared to single therapy or vehicle treatment(Figure 6B). Collectively, these data indicate that combin-
ation treatment of CtxR clones with U3-1287 and cetuxi-
mab can induce caspase-dependent apoptosis.
Figure 6 Cetuximab and U3-1287 induced apoptosis in CtxR clones. (A) Combinatorial treatment with cetuximab and U3-1287 activates
Caspase 3/7 compared to either drug alone in CtxR clones. Caspase-3/7 activity was determined by Caspase 3/7-Glo assay. Data represent
means ± s.e.m from 3 independent experiments (n = 9). *p <0.05 or **p <0.01. (B) The percentage of Annexin v-positive/propidium iodide-negative
cells was increased significantly after the combination of cetuximab and U3-1287 treatment compared to vehicle, cetuximab or U3-1287 alone in the CtxR
clones. Cells were plated and allowed to adhere for 24 h prior to treatment with vehicle, cetuximab (20 ug/mL), U3-1287 (50 ug/mL) or the combination of
cetuximab (20 ug/mL) and U3-1287 (50 ug/mL) for 24 h prior to Annexin-v analysis via flow cytometry. Data points are represented as
mean ± s.e.m. (n = 3). *p <0.05 or **p ≤0.001. Flow cytometry profile in HC4 cells represents Annexin-V-FITC staining in x-axis and PI in
y-axis. The number represents the percentage of cells in each condition.
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can overcome acquired resistance to cetuximab in vivo
To evaluate the efficacy of U3-1287 and cetuximab com-
bination treatment against tumor growth in vivo, a series
of mouse xenograft studies of de novo acquired resistance
to cetuximab [15,38] were established. To develop ac-
quired resistance to cetuximab in vivo, we inoculated
40 mice with the NSCLC line H226 unilaterally with
2 × 106 cells in the dorsal flank. Tumors were allowed
to grow to 100 mm3, at which time 30 mice were
treated with cetuximab (1 mg/mouse) twice weekly and
10 mice were treated with IgG control (1 mg/mouse)
twice weekly by intraperitoneal injection. IgG treated tu-
mors grew uninhibited, while cetuximab treated tumors
demonstrated tumor control and delayed growth. Tumors
were monitored for the development of cetuximab resist-
ance, defined as marked tumor growth in the presence of
continued cetuximab therapy. Once CtxR tumors reacheda volume of ~800 mm3, mice were grouped according to
tumor size at the time of resistance. CtxR was observed in
20 of 30 tumor xenografts (67%) treated with cetuximab,
similar to previous studies from our laboratory [15,38].
Thus, a total of six CtxR mouse xenograft groups were se-
lected for further study (18 mice in total). Upon establish-
ment of CtxR mouse groups, one mouse was maintained
on cetuximab (1 mg), one mouse was removed from
cetuximab and started on U3-1287 (500 ug) mono-
therapy, and another mouse was given the combination
treatment. The average tumor volume of mice treated
with IgG alone is included in all groups for comparison
purposes. Four out of 6 (67%) CtxR tumors treated with
U3-1287 and cetuximab demonstrated a tumor growth
delay compared to the mice that were maintained on
cetuximab monotherapy, while 2 (33%) tumors failed to
respond to U3-1287. In Figure 7A, the black arrow desig-
nates the starting time point of U3-1287 treatment. Mice
Figure 7 (See legend on next page.)
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Figure 7 Combination of cetuximab and U3-1287 treatment of CtxR tumors leads to growth delay in vivo. (A) Growth-delay effects of
U3-1287 in CtxR tumors in vivo. The black arrow designates the starting time point of U3-1287 treatment. The average tumor volume of mice treated
with IgG is included in all groups for comparison purposes. (B) Combination treatment with cetuximab and U3-1287 inhibited HER3 expression
and HER2 activation in vivo. Total and phosphorylation levels of HER2 and HER3 proteins in CtxR xenograft tumors were determined by immunoblot
analysis after cetuximab, U3-1287 or the combination of cetuximab and U3-1287 treatments. (C) The inhibition of phospho-HER3 and phospho-HER2
expression in CtxR tumors after combinatorial treatment corresponds with reduced proliferation and increased apoptosis. CtxR tumor samples after
cetuximab, U3-1287 or the combination of cetuximab and U3-1287 treatment in vivo were prepared and analyzed for Ki67 and cleaved caspase 3 by
immunohistochemistry. Images were quantified via taking the average staining intensity measured from 3 tumors per treatment group
(3 images/tumor, n = 9). Magnification 100X.
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and 4 demonstrated more robust anti-proliferative re-
sponse than tumors maintained on cetuximab or
switched to U3-1287 monotherapy. This anti-tumor re-
sponse was maintained for more than 30 days in the
dually treated mice. In contrast the tumor treated with
U3-1287 and cetuximab in Group 2 did not exhibit de-
layed tumor growth compared to the tumor treated with
U3-1287 alone. Analysis of tumor lysates harvested from
each treatment group indicated that phosphorylated
HER3 was significantly reduced in all tumors from U3-
1287 treated mice, while mice treated with dual ther-
apy exhibited even greater reductions in both total and
phosphorylated HER3 levels (Figure 7B). Additionally,
the mice treated with dual therapy that demonstrated
anti-proliferative responses in Figure 7A also expressed
less phosphorylated HER2 (Figure 7B). This observa-
tion may explain why U3-1287 and cetuximab dual
combination was more potent in these mice. Next, the
proliferation and apoptotic index of tumors from each
treatment group were examined by immunohistochem-
istry (Figure 7C). Ki67, a marker of actively proliferat-
ing cells, was robustly reduced in tumors treated with
dual therapy, while cleaved caspase 3, a marker of cells ac-
tively undergoing apoptosis, was significantly increased in
these tumors. Together, these data demonstrate that de
novo CtxR tumor xenografts can be sensitized to cetuxi-
mab induced growth delay upon inhibition of HER3 activ-
ity with U3-1287.
Discussion
While many patients initially respond to the anti-
EGFR mAb cetuximab, substantial clinical gains have
not been observed because resistance is inevitably the
outcome. In an attempt to study mechanisms of resist-
ance, several model systems have been established
where cetuximab sensitive cells are treated with increas-
ing doses of cetuximab until resistant clones emerge.
In the current study, we found that EGFR and HER3
cooperate in cetuximab resistant clones derived from
the NSCLC cell line H226. Targeting both HER3 and
EGFR with the neutralizing anti-HER3 mAb U3-1287
in combination with cetuximab led to robust anti-
proliferative effects and modest apoptotic effects inCtxR clones in vitro and in de novo models of acquired
resistance to cetuximab in vivo. These data suggest that
dual targeting HER family receptors with antibody-based
therapies can overcome acquired resistance to cetuximab
and provides rationale for the clinical movement of this
therapeutic strategy for the treatment of cetuximab-
resistant cancers.
HER3 is now known to play a major role in resistance to
both anti-HER2 and anti-EGFR therapeutics. In addition
to the current model, several investigators have observed
compensatory increases in HER3 activation post targeting
alternative HER receptors, indicating that HER3 can
maintain signaling pathways necessary for cancer cell pro-
liferation and survival when other HER receptors are
inhibited [24,39,40]. In the current study we found that
dual targeting both HER3 and EGFR led to a significant
loss in cellular proliferation (Figure 4A) and delayed
growth of CtxR tumors (Figure 7A). Interestingly, CtxR tu-
mors in Group 2 were sensitive to U3-1287, but U3-1287
addition to cetuximab did not provide any further benefit
(Figure 7A). Analysis of tumor lysate harvested from U3-
1287 and cetuximab treated mice in Group 2 indicated
that HER3 activation and expression was effectively down-
regulated, however, HER2 activity was not (Figure 7B).
The lack of HER2 blockade may be a reason why no fur-
ther benefit was detected upon dual therapy in Group 2.
While the current study focused on targeting the HER3
receptor as a method to overcome cetuximab resistance,
previous studies indicate that targeting HER2 can also
sensitize CtxR clones to cetuximab, with a parallel loss in
HER3 activity [18]. These findings highlight the necessity
of targeting both EGFR and the HER2:HER3 signaling
axes to achieve maximal anti-tumor responses. Our find-
ings are corroborated by independent studies in HNSCC,
CRC, and gastric cancer, where dual targeting of HER
family receptors can effectively overcome resistance to
anti-HER family monotherapies [41-43]. Collectively, our
data indicate that targeting multiple HER receptors is ne-
cessary for the complete inhibition of the HER family sig-
naling network, and may thus be a beneficial treatment
strategy for patients that have acquired resistance to
cetuximab.
The importance of knock down multiple HER family re-
ceptors is highlighted by analyzing oncogenic signaling
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current study, cetuximab treatment of CtxR clones re-
sulted in reduced MAPK activity, while U3-1287 resulted
in reduced AKT activity (Figure 5B); the combination of
both mAbs led to the simultaneous knockdown of both
pathways. The importance of inhibiting both signaling
pathways is highlighted by the fact that single HER family
mAb therapy did not augment CtxR cell proliferation or
survival (Figures 4 and 6). We speculate that CtxR cells
have compensatory mechanisms that allow for sustained
proliferation and survival upon knockdown of either
the AKT or MAPK signaling pathways, highlighting
the importance of targeting both pathways simultan-
eously. Additionally, there was a significant increase
in apoptosis post dual therapy in CtxR clones but not
in CtxS parental cells (Figure 6). This finding suggests
that CtxR cells are more highly dependent on both
cell survival and proliferation pathways, supporting
the necessity of dual targeting both AKT and MAPK.
Interestingly, HER2 activity was abrogated by dual
therapy in CtxR cells (Figure 5B), further demonstrat-
ing the importance of dual targeting HER family re-
ceptors to maximally inhibit the HER family signaling
network.
Neuregulin-1 (NRG-1) is the predominant ligand re-
sponsible for binding and activating HER3. Previous re-
ports from our laboratory have identified that EGFR
ligands, including EGF, heparin binding EGF, amphiregu-
lin, and β-cellulin were upregulated 2–9 fold in CtxR
clones [16]. In the current study, we found that CtxR
clones expressed 20–40 fold more NRG-1 compared to
the CtxS parental cells by qPCR (Figure 2B), where the
addition of NRG-1 to the CtxS parental cell line ren-
dered these cells resistant to cetuximab (Figure 2C).
These data indicate that NRG-1 autocrine signaling is a
major driver of cetuximab resistance in this model, which
was subsequently prevented through the degradation of
HER3 upon treatment with U3-1287. Similar to our findings,
increased NRG-1 secretion has been attributed to gefitinib
resistant breast cancer cells [44], and recently NRG-1 ren-
dered cells insensitive to trastuzumab-DM1 [45]. Further-
more, several growth factors have been shown to enhance
resistance to a plethora of different tyrosine kinase inhibitors
in cell line models [46]. Interestingly, increased HER family
ligands were shown to mediate resistance to anti-AKT inhib-
itors in triple-negative breast cancer cells, which was abro-
gated by targeting both EGFR and HER3 with a dual
receptor ligand-blocking antibody [47]. In attempt to combat
increased HER family ligand expression and autocrine
activation of HER receptors, mAbs targeting HER family
ligands may serve as potential therapeutics by sequester-
ing ligands prior to their activation of HER receptors. One
research group has developed a novel bispecific mAb that
can sequester EGFR ligands and NRG-1, resulting in anti-proliferative effects in several cancer models [48]. Re-
cently, a novel study generated mAbs directed against
NRG1 that demonstrated potent anti-tumor effects in
combination with chemotherapy in NSCLC models,
and prevented the expansion of residual tumor cells
post chemotherapy regimes [49]. Since excess HER family
ligands can manifest in cetuximab resistance (Figure 2C
and [16]), the use of mAb’s targeting HER family li-
gands in combination with anti-HER family mAb’s may
be highly beneficial in the CtxR setting. Overall, auto-
crine stimulation of HER receptors may play a critical
role in resistance to numerous therapeutic modalities,
and strengthens the need for dual targeting HER family
receptors.
Currently, there are several anti-HER3 mAbs being
evaluated for the treatment of cancer patients. Recent
studies investigating the use of a bispecific antibody
against EGFR and HER3, MEHD7945A, demonstrated
robust capability of overcoming resistance to both erloti-
nib and cetuximab in NSCLC and HNSCC cell models
[50]. While MEHD7945A was capable of reducing the
activation of HER3 in these cell systems, total HER3
levels remained constant. Neutralizing mAbs, such as
U3-1287, may have greater potential to elicit more ro-
bust anti-tumor effects in a variety of cancers due to
their ability to elicit receptor internalization and degrad-
ation rather than inhibiting ligand-induced activity. The
effective degradation of a receptor will bypass resistant
mechanisms such as receptor mutation, ligand overabun-
dance, and ligand-independent oncogenic properties of
RTKs. These mechanisms of resistance have borne out in
several studies with mAbs that only inhibit the ligand-
induced activity of EGFR such as the recent identification
of EGFR ligand binding domain mutations in cetuximab
resistant tumors [51]. Lantto et al. also demonstrated that
Sym013, a mixture of monoclonal antibodies targeting
EGFR, HER2 and HER3, inhibited proliferation in a large
number of cancer cell lines in vitro as well as multiple
xenograft models [52]. Sym013 resulted in the effective
degradation of all three HER family receptors, and pre-
vented the compensatory upregulation of alternative RTKs
both in vitro and in vivo modeling. Overall, cocktails of
neutralizing mAbs that elicit total HER family receptor
degradation may overtake the future of the HER family
targeting field.
Pre-clinical data suggests strong anti-tumor responses
in several cancer settings with U3-1287 in combination
with trastuzumab, and most recently in combination
with radiation therapy [53,54]. Furthermore, U3-1287 is
the most clinically advanced anti-HER3 mAb, where it
has been deemed safe and tolerable in phase I/II clinical
trials in advanced solid tumors [55,56]. U3-1287 is cur-
rently undergoing phase II trials in combination with
trastuzumab and paclitaxel in metastatic breast cancer,
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NSCLC (clinicaltrials.gov). Cumulatively, our data as
well as others, indicate that dual targeting HER family
receptors may induce robust anti-tumor responses, and
thus may be a beneficial treatment strategy for cetuxi-
mab resistant cancers.Conclusions
In the current study, we found that EGFR and HER3
collaborate in cetuximab resistant clones derived from
the NSCLC cell line H226. Targeting both HER3 and
EGFR with the neutralizing anti-HER3 monoclonal anti-
body U3-1287 in combination with cetuximab led to ro-
bust anti-proliferation effects and modest apoptotic effects
in CtxR clones in vitro and in de novo models of acquired
resistance to cetuximab in vivo. Our data suggest that dual
targeting HER family receptors with antibody-based ther-
apies can overcome acquired resistance to cetuximab and
provide rationale for the clinical movement of this thera-
peutic strategy for the treatment of cetuximab-resistant
cancers.Materials and Methods
Cell lines
The human NSCLC cell line H226 was provided by Drs.
Minna J. and Gazdar A. (University of Texas Southwestern
Medical School, Dallas, TX). The cells were maintained in
10% fetal bovine serum in RPMI-1640 (Mediatech Inc.,
Manassas, VA, USA) with 1% penicillin and streptomycin.
The development of CtxR clones has been previously
described [18].Small interfering RNA and transfection
For small interfering RNAs (siRNAs), CtxR cells (HC1,
HC4 and HC8) were transiently transfected with siEGFR
(ON-TARGETplus, SMART pool #L-003114-00, Dharma-
con, Lafayette, CO, USA) and siHER3 (ON-TARGETplus,
SMART pool #L-003127-00, Dharmacon) using Lipofecta-
mine RNAiMAX according to the manufacturer's instruc-
tions (Invitrogen, Carlsbad, CA, USA). The non-targeting
siRNA (ON-TARGETplus Non-targeting Pool, #D-001810-10)
was obtained from Dharmacon as a control. Cells were
then lysed for analysis of protein knockdown by immuno-
blotting after siRNA transfection.Materials
Neuregulin 1 was obtained from R&D Systems (Minneapolis,
MN, USA). Cetuximab (ICM-225, Erbitux) was purchased
from University of Wisconsin Pharmacy. U3-1287 was
generously provided by U3 Pharma GmbH (Martinsried,
Germany).Antibodies
All antibodies were purchased from commercial sources as
indicated below: EGFR, pEGFR (Y1173), HER2, HER3 and
HRP-conjugated goat-anti-rabbit IgG and goat-anti-mouse
IgG were obtained from Santa Cruz Biotechnology Inc.
(Dallas, TX, USA). pHER3 (Y1289), pHER3 (Y1197),
pHER2 (Y1248), pAKT (S473, T308), pMAPK (T202/
Y204), MAPK, p-p90RSK (S380), RSK1/2/3, pSTAT3
(S727), STAT3, cleaved caspase-3 and Ki67 were obtained
from Cell Signaling Technology (Danvers, MA, USA).
α-Tubulin was purchased from Calbiochem (Billerica,
MA, USA).
Cell proliferation assay
Equal numbers of cells were seeded in 6 well plates. Fol-
lowing treatment, monolayers were washed with PBS
and fixed/stained with 0.5% crystal violet. Plates were air
dried overnight and dye was eluted with 0.1 M sodium
citrate (pH 4.2) in ethanol (1:1). Elution was transferred
to 96-well plates, and the absorbance was read at
540 nm to determine cell proliferation. All treatments
were performed in triplicate. Cells were also seeded at
2,000 cells per well in 100 μl of media on a 96 well plate,
grown for 24 h and then treated with drug for 72 h prior to
analysis using the Cell Counting Kit 8 (Dojindo Molecular
Technologies, Rockville, MD) according to the manu-
facture’s instructions. All treatments were performed
in quadruplicate.
Immunoblotting analysis
Whole cell protein lysate was obtained by tween-20 lysis
buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 0.1%
Tween-20, 10% glycerol, 2.5 mM EGTA, 1 mM EDTA,
1 mM DTT, 1 mM Na3VO4, 1 mM PMSF, 1 mM BGP
and 10 μg/ml of leupeptin and aprotinin). Samples were
sonicated and then centrifuged at 15,000 g for 10 min at
4°C. Protein concentrations were determined by Bradford
assay (Bio-Rad Laboratories, Hercules, CA, USA). Equal
amounts of protein were fractionated by SDS-PAGE,
transferred to a PVDF membrane (Millipore, Billerica,
MA, USA), and analyzed by incubation with the appropri-
ate primary antibody. Proteins were detected via incuba-
tion with HRP-conjugated secondary antibodies and ECL
Western Blotting Substrate (Promega Cooperation, Madison,
WI, USA), SuperSignal* West Dura Extended Duration
Chemiluminescent Substrate or SuperSignal* West Femto
Maximum Sensitivity Chemiluminescent Substrate (Thermo
Fisher Scientific, Waltham, MA, USA).
Immunoprecipitation
Cells were lysed with NP-40 lysis buffer (50 mM HEPES,
pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid,
10% glycerol, 2.5 mM EGTA, 1 mM EDTA, 1 mM DTT,
1 mM PMSF, 1 mM BGP and 10 mg/ml of leupeptin
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were incubated overnight at 4°C with 200 ug/mL of anti-
rabbit EGFR or anti-rabbit HER3 antibodies. After add-
ing 30 uL of protein A/G agarose beads (Santa Cruz),
cell lysates were incubated for another 2 h at 4°C. The
immunoprecipitates were pelleted by centrifugation and
washed several times with NP-40 lysis buffer. The cap-
tured immunocomplexes were then eluted by boiling the
beads in 2xSDS sample buffer for 5 min and subjected
to immunoblot analysis as described above.
cDNA synthesis and qPCR
Total RNA from cells was prepared using an RNeasy
Mini kit (Qiagen, Inc., Valencia, CA). cDNA from total
RNA of HP, HC1, HC4 and HC8 were synthesized using
qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg,
MD, USA). qPCR analysis was performed using a Bio-Rad
CFX96 Real-Time PCR Detection System (Bio-Rad Labora-
tories) using the iQ Supermix as recommended by manufac-
turer. All reactions were performed in quadruplicate. The
NRG1 primer sets (Hs00247624_m1) used for this analysis
were purchased from Life Technologies TaqMan Gene
Expression Assay. Fold increases in gene expression
were determined by quantitation of cDNA from target
samples (HC1, HC4 and HC8) relative to a calibrator
sample (HP). Human β-actin gene (F: 5′-CAGCCATG
TACGTTGCTATCCAGG-3′, R: 5′-AGGTCCAGACG
CAGGATGGCATG-3′) was used as the endogenous
control for normalization of initial RNA levels. To deter-
mine this normalized value, 2-ΔΔCT values were compared
references between target and calibrator samples, where
the change in crossing threshold ΔCt = CtNRG1-Ctβ-actin
and ΔΔCt =ΔCtHC1, HC4 or HC8-ΔCtHP.
Flow cytometric analysis
Cells were washed in PBS and harvested with PBS-EDTA
(0.02% solution). A cell suspension containing 1 × 106 cells
in 100 uL flow buffer (PBS containing 1% FBS) was incu-
bated with 1 ug of either control IgG, anti-EGFR fluorescein
isothiocyanate (FITC)-conjugated antibodies or anti-HER3
PE-conjugated antibodies (Santa Cruz Biotechnology Inc.)
for 30 min on ice. Cells were washed and resuspended
in 500 uL of flow buffer. Propidium iodide (PI) was
added to each sample just before analysis on the cyt-
ometer. Samples were analyzed on a FACSCalibur flow
cytometer (BD Biosciences, San Jose, CA, USA) and a
minimum of 10,000 live events per sample was ac-
quired. Histogram analysis was performed with FlowJo
software (Tree Star Inc., Ashland, OR, USA). Data
were restricted to live events based on PI exclusion.
Phospho-kinase array
CtxR cell line (HC4) was analyzed in the panel of phosphor-
ylation profiles of kinases after treatment with cetuximab,U3-1287 and a combination of cetuximab and U3-1287
agents (Human Phospho-Kinase Array, ARY003; R&D Sys-
tems). This array specifically screens for relative levels of
phosphorylation of 46 individual proteins involved in cellu-
lar proliferation and survival. After 24 h of treatment with
cetuximab (20 ug/mL), U3-1287 (100 ug/mL) and their
combination, cells were harvested and cell lysates were in-
cubated with the membrane. Thereafter, a cocktail of
biotinylated detection antibodies, streptavidin–horse-
radish peroxidase and chemiluminescent detection re-
agents were used to detect the phosphorylated protein.
The relative expression of specific phosphorylated protein
was determined following quantification of scanned im-
ages by ImageJ compared with cetuximab, U3-1287, their
combination and vehicle.
Annexin-V apoptosis assay
An amount of 800,000 cells were plated in 100 mm
plates and after 24 h of incubation treated with vehicle,
20 ug/mL cetuximab, 50 ug/mL U3-1287 or the combin-
ation for 24 h. Cells were harvested after trypsinization.
Next, cells were washed with PBS, re-suspended in bind-
ing buffer (BD Biosciences) and stained with FITC
Annexin-V (FITC Annexin-V apoptosis detection kit,
BD Biosciences). The cells were analyzed by flow cytom-
etry (BD FACScan). FlowJo Software (Tree Star, Inc.)
was used to analyze the data. All experimental arms
were done in triplicate and displayed as averages with
standard error bars.
Caspase 3/7 activity assay
Caspase 3/7 activity assay was performed by manufac-
ture’s protocol (Promega). Briefly, CtxR clones were
plated in a white-walled 96-well plate. Cells were treated
with vehicle, 20 ug/mL cetuximab, 50 ug/mL U3-1287
or the combination for 24 h. After adding 100 μL of
Caspase 3/7 reagent and mix gently, the cells were incu-
bate for 1 h at room temperature, and the luminescence
of each sample was measured by luminometer (Enspire
plate reader, Perkin Elmer, Waltham, MA). Caspase 3/7
assay was carried out in triplicate.
Mouse cetuximab-resistant human tumor xenografts
Athymic nude mice (4- to 6-week old; male) were ob-
tained from the Harlan Laboratories (Indianapolis, IN,
USA). All animal procedures and maintenance were
conducted in accordance with the institutional guide-
lines of the University of Wisconsin. Mice were injected
with H226 (2x106 cells) and tumors were allowed grow
to 100 mm3. All mice were randomized to treatment or
control groups and treated with 1 mg/mouse (40 mg/kg)
of either Cetuximab or IgG intraperitoneally twice per
week. Tumors were monitored for cetuximab resistance
that was defined as marked tumor growth in the
Iida et al. Molecular Cancer 2014, 13:242 Page 14 of 16
http://www.molecular-cancer.com/content/13/1/242presence of continued cetuximab therapy. Once CtxR tu-
mors reached a volume ~800 mm3, mice were grouped ac-
cording to similar time points of resistance. At this point
each mouse was treated with cetuximab, 500 ug of U3-1287
or the combination of cetuximab and U3-1287 intraperito-
neally twice per week. Tumor volume measurements were
evaluated by digital calipers and calculated by the formula
(p)/6 x (large diameter) × (small diameter)2.
Mouse tumor collection and protein isolation
Tumors were collected 24 hours after last treatment. Mice
were sedated using isofluorane mixed with oxygen, which
was administered until loss of consciousness. Mice were eu-
thanized by cervical dislocation and tumors were promptly
collected, washed in PBS, and frozen with isopentane on dry
ice. Whole cell protein lysates from tumor samples were ob-
tained with NP-40 lysis buffer, homogenized by 10 strokes
in a tightly fitting Dounce homogenizer, and quantified. Pro-
tein quantitation and immunoblotting analysis were per-
formed as stated above.
Immunohistochemistry
Tumor tissue samples were collected from xenograft tu-
mors. Tumor samples were fixed in 10% neutral buffered
formalin and paraffin embedded. Sections were heated
in 10 mM citrate buffer (pH6.0) for Ki67 and cleaved
caspase-3 by Decloaking chamber. Samples were incu-
bated with rabbit anti Ki67 (1:400) and rabbit anti cleaved
caspase-3 (1:200). Sections were stained by the Universal
Quick kit (Vector laboratories, Inc., PK-8800, Burlingame,
CA, USA). Antibody binding was revealed by addition of
3,3′-diaminobenzidine substrate (Thermo Fisher). Tissues
were counterstained with Mayer’s hematoxylin (Thermo
Fisher). Tissues were examined using an Olympus BX51
microscope. Quantitation of staining intensity was per-
formed with ImageJ.
Statistical analysis
Student t-tests were used to evaluate the significance of
changes in all expression assays compared to non-
targeting controls. Differences were considered statisti-
cally significant if P ≤ 0.05.
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